DexCom Inc (DXCM)
BiotechSign Signal Grade
Composite of clinical trial activity, dilution exposure, publications, short interest, and insider transactions — all from verified public filings.
Pipeline Overview
- Therapeutic Focus
- Diabetes Techsrc
Clinical Trial Activity
(ClinicalTrials.gov aggregate)
ClinicalTrials.gov aggregate as of 2026-10-13. ClinicalTrials.gov
Dilution Risk
LOW DILUTION RISKDilution score: 10/100 (LOW), cash runway not available
Derived from verified regulatory filings. Measures dilution exposure from warrants, convertibles, and offering history. DilutionWatch SEC-derived score
Short Interest
Short interest: 3.65% of float, squeeze risk: MODERATE
FINRA short sale data. FINRA short interest
Recent News & SEC Filings
- NEJM study supports CGM use for people with diabetes who don’t take insulin
- Landmark Dexcom CONNECT Study Published in The New England Journal of Medicine, Redefining the Standard of Care for People with Type 2 Diabetes Not on Insulin
- Here's Why You Should Retain DexCom Stock in Your Portfolio for Now
- mHealth Solutions Market Forecasts Growth from $109.05B (2026) to $275.44B by 2031, Profiling Philips, Medtronic, Abbott, Dexcom, ResMed & 20 Other Key Players
- Here's What to Expect From DexCom’s Next Earnings Report
- Dexcom Schedules Third Quarter 2026 Earnings Release and Conference Call for October 29, 2026 at 4:30 p.m. Eastern Time
- Dexcom U Enters Season 5 With a Record Roster and Evidence That Diabetes Stigma Among Young Athletes Is Fading
- DXCM Report Highlights CGM Growth Opportunity in Type 2 Diabetes Care
Headlines from public sources. BiotechSign does not endorse or verify linked content.
Recent Publications
- Individualising blood glucose control in ICU patients: evidence and practical implementations. — Crit Care 2026 Sep 9 PMID 42745269
- Postpartum GLP-1 receptor agonists and SGLT-2 therapies in women with prior gestational diabetes: current evidence and uncertainties. — BMC Med 2026 Aug 22 PMID 42717332
- Pain alleviation in diabetic neuropathy using hybrid closed loop insulin pumps (PAINLESS) - A randomised crossover trial protocol. — PLoS One 2026 PMID 42709726
- Extended Use of the Omnipod 5 Automated Insulin Delivery System in Adults With Type 1 Diabetes: 12-Month Extension of a Randomized Controlled Trial. — Endocrinol Diabetes Metab 2026 Sep PMID 42671087
- Adherence to Sedative Weaning Opportunities and Length of Stay for Critically Ill Children. — JAMA Netw Open 2026 Aug 3 PMID 42627664
Get real-time catalyst alerts, analyst signals, dilution risk tracking, and full pipeline data for DexCom Inc.
Full DXCM Dashboard Sign Up FreePrimary Sources
This page reports only records present in the BiotechSign source payload as of the generation date. It does not infer drug efficacy, clinical outcome probability, approval odds, revenue, market size, or unreported regulatory events.